Linking neurotransmission, guidelines and clinical practice in AD
Location
Fairmont Vancouver Hotel
Reception: 5:30-6 p.m.
Symposium: 6-7:30 p.m.
Sponsorship
Merz |
 |
Clinical efficacy of memantine and acetylcholinesterase inhibitors as monotherapies for treatment of Alzheimer disease (AD) is well documented. Preclinical rationale and clinical evidence from large-scale, robustly designed studies make combined treatment with memantine and donepezil a natural option for the moderate stages of AD onwards. The treatment is supported by health economic analyses and acknowledged in many treatment guidelines worldwide.
|
Monday, July 16th, 2012 |
6-7:30 p.m. |
|
|
Managing functional decline in Alzheimer’s disease: can we do more?
Location
Fairmont Waterfront Ballroom
Sponsorship
Novartis |
 |
International experts will discuss current needs in Alzheimer’s disease management, focusing on functional decline and its impact on the patient/caregiver. The scientific rationale for cholinesterase inhibition, including latest approaches to treatment with cholinesterase inhibitors, will be explored in the context of data from a recent clinical trial of rivastigmine patch. |
Tuesday, July 17th, 2012 |
6-7:30 p.m. |
|
|
β-Amyloid in ALZHEIMER’S DISEASE
An Evidence-Based Synthesis
Location
Fairmont Waterfront Ballroom
Sponsorship
Lilly |
 |
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked in part by an accumulation of beta-amyloid, a product of aberrant proteolysis. In this Interactive Forum, the evidence supporting a pathogenic role for beta-amyloid will be explored across the spectrum of AD, from the preclinical phase through clinical dementia. Faculty will examine emerging insights into early diagnosis and amyloid-based disease-modifying strategies. |
